Please use this identifier to cite or link to this item:
https://doi.org/10.1158/0008-5472.CAN-19-0343
Title: | IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma | Authors: | Chong, Phyllis SY Zhou, Jianbiao Lim, Julia SL Hee, Yan Ting Chooi, Jing-Yuan Chung, Tae-Hoon Tan, Zea Tuan Zeng, Qi Waller, Daniel D Sebag, Michael Chng, Wee-Joo |
Keywords: | Science & Technology Life Sciences & Biomedicine Oncology MOLECULAR CLASSIFICATION PHOSPHATASE PRL-3 INTERLEUKIN-6 METASTASIS TYROSINE TRANSCRIPTION ACTIVATION CANCER BORTEZOMIB APOPTOSIS |
Issue Date: | 15-Sep-2019 | Publisher: | AMER ASSOC CANCER RESEARCH | Citation: | Chong, Phyllis SY, Zhou, Jianbiao, Lim, Julia SL, Hee, Yan Ting, Chooi, Jing-Yuan, Chung, Tae-Hoon, Tan, Zea Tuan, Zeng, Qi, Waller, Daniel D, Sebag, Michael, Chng, Wee-Joo (2019-09-15). IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma. CANCER RESEARCH 79 (18) : 4679-4688. ScholarBank@NUS Repository. https://doi.org/10.1158/0008-5472.CAN-19-0343 | Abstract: | © 2019 American Association for Cancer Research. Overexpression of PRL-3, an oncogenic phosphatase, was identified as a novel cluster in patients with newly diagnosed multiple myeloma. However, the regulation and oncogenic activities of PRL-3 in multiple myeloma warrant further investigation. Here, we report that IL6 activates STAT3, which acts as a direct transcriptional regulator of PRL-3. Upregulation of PRL-3 increased myeloma cell viability and rephosphorylated STAT3 in a biphasic manner through direct interaction and deactivation of SHP2, thus blocking the gp130 (Y759)-mediated repression of STAT3 activity. Abrogation of PRL-3 reduced myeloma cell survival, clonogenicity, and tumorigen-esis, and detailed mechanistic studies revealed "deactivation" of effector proteins such as Akt, Erk1/2, Src, STAT1, and STAT3. Furthermore, loss of PRL-3 efficiently abolished nuclear localization of STAT3 and reduced its occupancy on the promoter of target genes c-Myc and Mcl-1, and antiapoptotic genes Bcl2 and Bcl-xL. PRL-3 also played a role in the acquired resistance of myeloma cells to bortezomib, which could be overcome by PRL-3 silencing. Of clinical relevance, STAT3 and PRL-3 expression was positively correlated in five independent cohorts, and the STAT3 activation signature was significantly enriched in patients with high PRL-3 expression. Furthermore, PRL-3 could be used as a biomarker to identify high-risk patients with multiple myeloma that exhibited poor prognosis and inferior outcome even when treated with novel combinational therapeutics (proteasome inhibitors and immunomodulatory imide drugs). Conclusively, our results support a feedforward mechanism between STAT3 and PRL-3 that prolongs prosurvival signaling in multiple myeloma, and suggest targeting PRL-3 as a valid therapeutic opportunity in multiple myeloma. Significance: IL6 promotes STAT3-dependent transcriptional upregulation of PRL-3, which in turn re-phosphorylates STAT3 and aberrantly activates STAT3 target genes, leading to bortezomib resistance in multiple myeloma. | Source Title: | CANCER RESEARCH | URI: | https://scholarbank.nus.edu.sg/handle/10635/166530 | ISSN: | 00085472 15387445 |
DOI: | 10.1158/0008-5472.CAN-19-0343 |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
PRL-3 Multiple Myeloma.pdf | Published version | 1.05 MB | Adobe PDF | CLOSED | None |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.